NCT02121522

A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

A Single Arm Open Label Study to Evaluate the Pharmacodynamics and Safety of a 4 wk Treatment With BI 144807 in Patients With Newly Diagnosed Wet Age Related Macular Degeneration (wAMD)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The present trial will use an open label design to investigate the effect of BI 144807 on central 1-mm retinal thickness and presence of neovascular leakage in newly diagnosed wAMD patients. A further objective is to collect data on adverse events, vital signs, ECG and clinical laboratory parameters of BI 144807 in the same patient group.

Conditions

• Wet Macular Degeneration

Interventions

Type	Name	Description
DRUG	BI 144807	twice daily

Timeline

• Start date: 2014-06-01
• Primary completion: 2015-03-01
• Completion: 2015-04-01
• First posted: 2014-04-23
• Last updated: 2016-06-27
• Results posted: 2016-06-27

Locations

10 sites across 3 countries: Austria, Germany, Hungary